WO2004058256A1 - Pharmaceutical liquid composition containing pyridone derivative - Google Patents

Pharmaceutical liquid composition containing pyridone derivative Download PDF

Info

Publication number
WO2004058256A1
WO2004058256A1 PCT/JP2003/016599 JP0316599W WO2004058256A1 WO 2004058256 A1 WO2004058256 A1 WO 2004058256A1 JP 0316599 W JP0316599 W JP 0316599W WO 2004058256 A1 WO2004058256 A1 WO 2004058256A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid composition
pharmaceutical liquid
composition according
pirfenidone
diethylene glycol
Prior art date
Application number
PCT/JP2003/016599
Other languages
French (fr)
Inventor
Pyare L. Seth
Original Assignee
Kdl, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kdl, Inc. filed Critical Kdl, Inc.
Priority to AU2003292551A priority Critical patent/AU2003292551A1/en
Priority to US10/540,422 priority patent/US7605173B2/en
Priority to DE60332393T priority patent/DE60332393D1/en
Priority to EP03768187A priority patent/EP1575585B1/en
Publication of WO2004058256A1 publication Critical patent/WO2004058256A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention relates to a pharmaceutical liquid composition containing a pyridone derivative. More particularly, it relates to a pharmaceutical liquid composition containing as the active ingredient a pyridone derivative such as 5- methyl-l-phenyl-2- (IH) -pyridone (Pirfenidone) and the like, which is effective in the treatment of dermatological disorders, particularly fibrotic dermatoses such as fibrotic lesional tissues, contiguous warts and the like or contact dermatitis, keloids, scars after burn surgery and the like.
  • a pyridone derivative such as 5- methyl-l-phenyl-2- (IH) -pyridone (Pirfenidone) and the like, which is effective in the treatment of dermatological disorders, particularly fibrotic dermatoses such as fibrotic lesional tissues, contiguous warts and the like or contact dermatitis, keloids, scars after burn surgery and the like.
  • Said liquid compositions containing the pyridone derivative in the high concentrations, with the absence of recrystallization is stable for a long period of time and suitable to be administered orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip.
  • the 5-methyl-l- phenyl-2- (IH) -pyridone has found a broad spectrum of applications in the prevention and treatment of fibrotic disorders, particularly in the reparation and prevention of fibrotic lesional tissues, contiguous warts, contact dermatitis, keloids, fibrosis of the lung, fibrosis and hypertrophy of the prostate, nephrosclerosis and the like; and useful in the treatment of scars after burn surgery, Alzheimer' s disease and the like.
  • These literatures have described that the Pirfenidone is generally administered orally or percutaneously or by injection.
  • a gel formulation for topical administration comprising a gel-forming agent such as carboxypolymethylene, a plasticizer such as polypropylene, an antioxidant such as sodium metabisulfite and a pH adjusting agent such as sodium hydroxide.
  • the gel formulation has been described as excellent in stability without the recrystallization of the active ingredient even after it is stored at various temperatures for a long period of time.
  • the highest possible concentration of active ingredient is 7% by weight in these gel formulations and it cannot be said that the formulations are capable of containing the active ingredient in a sufficiently high concentration.
  • DMSO dimethylsulfoxide
  • Pirfenidone in a high concentration of more or less 25% by weight can be obtained by dissolving the active ingredient in a diethylene glycol monoethyl ether that is a medical solvent called Transcutol-P and described and its safety confirmed in the European and US pharmacopeias. It has also been found that the so obtained composition does not recrystallize if stored for a long period of time, able to be administered either orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip and certain to make a pharmaceutical composition excellent in every point. The present invention has been brought to completion on the basis of these findings .
  • the present invention provides a pharmaceutical liquid composition
  • a pharmaceutical liquid composition comprising as an active ingredient a pyridone derivative represented by the following formula (I) :
  • R 1 is an alkyl group optionally having a substituent and R 2 is a phenyl group optionally having a substituent or a pharmaceutically acceptable salt thereof, and a . solvent .capable of dissolving said active ingredient in a high concentration.
  • the pharmaceutical liquid composition of the present invention comprises as the active ingredient a pyridone derivative represented by the above-mentioned formula (I) or a pharmaceutically acceptable salt thereof.
  • a pyridone derivative represented by the above-mentioned formula (I) or a pharmaceutically acceptable salt thereof.
  • R 1 is an alkyl group optionally having a substituent and R 2 is a phenyl group optionally having a substituent.
  • the examples of the alkyl group optionally having a substituent as R 1 include a C 1-6 lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl and an alkyl group having a substituent in which said lower alkyl group is substituted with a halogen atom such as fluorine or chlorine; a carboxyl group; an alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl; or a substituent such as amino group.
  • the alkyl group optionally having a substituent as R 1 may be substituted at any of the 3-position, 4-position or 5-position.
  • the examples of the phenyl group optionally having a substituent as R 2 include a phenyl group and a phenyl group having a substituent in which the phenyl group is substituted with a C x _ 6 lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl; a halogen atom such as fluorine or chlorine; a carboxyl group; an alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl; or a substituent such as amino group.
  • a C x _ 6 lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl
  • a halogen atom such as fluorine or chlorine
  • a carboxyl group an alkoxycarbonyl group such as
  • the pyridone derivative as the active ingredient it is preferable to use the 5-methyl-l- phenyl-2- (IH) -pyridone (Pirfenidone) wherein R 1 is a methyl group substituted at the 5-postion and R 2 is a phenyl group.
  • the pyridone derivative as the active ingredient may be a pharmaceutically acceptable salt thereof.
  • the examples of the salt include an acid addition salt, a salt with alkali or the like.
  • the example of the acid addition salt include an acid addition salt with an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, paratoluene sulfonic acid or methane sulfonic acid.
  • the example of the salt with alkali includes a salt such as sodium salt or potassium salt.
  • a salt such as sodium salt or potassium salt.
  • the diethylene glycol monoethyl ether also known as ethoxy diglycol or diethylene glycol ethyl ether
  • the diethylene glycol monoethyl ether is a compound represented by the following chemical formula:
  • the compound occurs as colorless and transparent, well miscible with water, and has been marketed by the name of Transcutol P as a commonly used solvent. It has also been known that the compound can be used as an absorption promoter in medicine (Ritschel, W. et al . , Skin Pharmacol., (1191) 4, 235-245) . In the present invention, it is preferable to use the diethylene glycol monoethyl ether having a purity of 99% or higher, more preferably 99.7% or higher and most preferably 99.9% or higher.
  • the present invention has demonstrated that the Pirfenidone can be dissolved in a very high concentration ' of more or less 25% by weight by selecting the diethylene glycol monoethyl ether among others as the solvent for Pirfenidone and thus that a liquid medicinal composition containing the Pirfenidone in a very high concentration can be obtained.
  • This high concentration corresponds to the 300 mg dose of the drug in a solution of 2 ml, almost equivalent to the dosage of the same drug in common tablets presently used for oral administration.
  • the liquid medicinal composition of the present invention can contain a concentrating agent, antioxidant, dispersant, viscosity adjusting agent, diluent, antimicrobial and the like that are commonly used in medicinal formulations, depending upon the method of administration, the route of administration, the specific type of formulation and the like.
  • the examples of the concentrating agent include polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and the like.
  • the examples of the antioxidant include sodium metabisulfite, ⁇ -tocopherol, sodium ascorbate and the like.
  • the examples of the dispersant include polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose and the like.
  • the examples of the viscosity adjusting agent include bentonite, calcium magnesium silicate and the like.
  • the examples of the diluent include methanol, ethanol and the like.
  • the examples of the antimicrobial include benzalkonium chloride, benzethonium chloride, methylparaben, ethylparaben and the like.
  • the liquid composition of the present invention has a broad spectrum of application in the administration via oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, injection or intravenous drip and the like.
  • the highly concentrated solution dissolving the pyridone derivative such as Pirfenidone in the solvent comprising diethylene glycol monoethyl ether is partially separated and the so separated liquid is diluted with water or fruit juice to make a pharmaceutical formulation for oral administration.
  • the liquid composition of the present invention dissolves in a high concentration Pirfenidone which is slightly soluble in water by nature, accompanied by the hydration property permitting the composition to be diluted 4 to 5 times with water and make a pharmaceutical formulation for oral administration with ease.
  • the liquid composition of the present invention is very low in viscosity and can be filled into a pump spray as a spray formulation ' or into a roll-on container for use in oral, nasal or vaginal administration. Moreover, it also can be filled into, for example, a vaporizer such as nebulizer, to make a pharmaceutical formulation for vaporizing administration. Furthermore, an injection or intravenous drip can be prepared from the composition by adding isotonic physiological saline thereto. With respect to the liquid composition of the present invention, the preferred specific examples will be shown below:
  • Purified water 0-25 Ingredients % by weight Pirfenidone 10-25 Diehtylene glycol monoethyl ether 75-80 Purified water 0-10
  • the pharmaceutical liquid compositions were prepared from the formulations listed in Table 1.
  • the diethylene glycol monoethyl ether was charged to a suitable container and warmed to 60 °C.
  • the Pirfenidone was added while stirring and a yellowish solution was obtained by continuing the stirring until the mixture was transparent. All the remaining ingredients as listed in Table 1 were dissolved in water at 60 °C and this solution was poured into the above Pirfenidone solution and the stirring was continued . until mixed uniformly. The so obtained solution was protected from the light.
  • the solutions of Examples 1 and 2 were found to have the viscosity similar to that of water. It was found that the solution of Example 5 had the slightly higher viscosity but was not in a state of gel and still pourable, while. the solutions of Examples 3 and 4 were found to have the viscosity similar to that of water.
  • the liquid compositions containing the Pirfenidone in the high concentrations could be obtained by dissolving the Pirfenidone in the diethylene glycol monoethyl ether.
  • the liquid compositions were prepared, having the formulations listed in Table 2.
  • the diethylene glycol monoethyl ether was charged to a suitable container and warmed to 60 °C, and the Pirfenidone was added while stirring and a yellowish solution was obtained by continuing the stirring until the whole became transparent.
  • the ⁇ -tocopherol was added and water was added while stirring until mixed uniformly. Then, the hydroxypropyl cellulose was added because of its necessity and stirred until a homogenous dispersion was formed. Furthermore, the dispersion was allowed to stand overnight until the particles of hydroxypropyl cellulose, the concentrating agent, were expanded, and finally the product was homogenized. The so obtained dispersion was allowed to stand overnight and a solution in the desired concentration was obtained.
  • the liquid compositions containing the Pirfenidone in the high concentrations could be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether.
  • the Pirfenidone is dissolved in diethylene glycol monoethyl ether, with the result that the liquid medicinal compositions containing the Pirfenidone in very high concentrations of more or less 25% by weight are obtained.
  • these liquid compositions are stored at low temperatures for a long period of time, the Pirfenidone will not be recrystallized with a good chemical and physical stability.
  • the liquid compositions have a broad spectrum of application in manufacturing the various different pharmaceutical formulations for use in administration via oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, Injection or intravenous drip.
  • liquid compositions can undergo the sterilization in the manufacturing process for injections or intravenous drips and are well miscible when they are diluted in water and non- irritating when applied to the open wounds. Even if the liquid medicinal compositions are contained in non- aqueous pharmaceutical formulations, they will be very stable, having many different advantages.

Abstract

A pharmaceutical liquid composition containing the Pirfenidone in a very high concentration of more or less 25% by weight can be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether. Even when the liquid medicinal compositions are stored for a long period of time, the Pirfenidone will not be recrystallized with a good chemical and physical stability. Furthermore, the liquid compositions are little irritating to the wounds on the mucous membrane of the skin and suitable for the manufacture of pharmaceutical formulations to be administered either via the oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, injection or intravenous drip.

Description

DESCRIPTION PHARMACEUTICAL LIQUID COMPOSITION CONTAINING PYRIDONE DERIVATIVE
TECHNICAL FIELD
The present invention relates to a pharmaceutical liquid composition containing a pyridone derivative. More particularly, it relates to a pharmaceutical liquid composition containing as the active ingredient a pyridone derivative such as 5- methyl-l-phenyl-2- (IH) -pyridone (Pirfenidone) and the like, which is effective in the treatment of dermatological disorders, particularly fibrotic dermatoses such as fibrotic lesional tissues, contiguous warts and the like or contact dermatitis, keloids, scars after burn surgery and the like. Said liquid compositions containing the pyridone derivative in the high concentrations, with the absence of recrystallization is stable for a long period of time and suitable to be administered orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip.
BACKGROUND OF THE INVENTION As described in US Patent No. 5,310,562 and
European Laid-Open Patent No. 0383591, the 5-methyl-l- phenyl-2- (IH) -pyridone (Pirfenidone) has found a broad spectrum of applications in the prevention and treatment of fibrotic disorders, particularly in the reparation and prevention of fibrotic lesional tissues, contiguous warts, contact dermatitis, keloids, fibrosis of the lung, fibrosis and hypertrophy of the prostate, nephrosclerosis and the like; and useful in the treatment of scars after burn surgery, Alzheimer' s disease and the like. These literatures have described that the Pirfenidone is generally administered orally or percutaneously or by injection.
With respect to the Pirphenidone pharmaceutical formulations, International Published Application WO00/16775 has described a gel formulation for topical administration, comprising a gel-forming agent such as carboxypolymethylene, a plasticizer such as polypropylene, an antioxidant such as sodium metabisulfite and a pH adjusting agent such as sodium hydroxide. The gel formulation has been described as excellent in stability without the recrystallization of the active ingredient even after it is stored at various temperatures for a long period of time. However, the highest possible concentration of active ingredient is 7% by weight in these gel formulations and it cannot be said that the formulations are capable of containing the active ingredient in a sufficiently high concentration.
Attempts to make the highly concentrated formulations by using alcohol-based solvents as the solution-forming agent would be frustrated because the solvents irritate the mucous membrane, give rise to pains in open wounds and are not acceptable clinically. In Europe and USA, dimethylsulfoxide (DMSO) has been incorporated into the pharmaceutical formulations for external use as the additive unaccompanied by irritation to the mucous membrane and capable of increasing the solubility of Pirfenidone. However, the DMSO has been found to be problematical from the viewpoint of safety.
DISCLOSURES OF THE INVENTION
Thus, it has been desired to develop a liquid pharmaceutical formulation capable of containing Pirfenidone as the active ingredient in a high concentration, with the absence of recrystallization during the longtime storage, stable chemically and physically and suitable to be administered either orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip without causing any problems from the viewpoint of safety.
An intensive investigation was conducted with a view to finding a means for solving the above- mentioned problems. As a result, it has been found that a pharmaceutical liquid composition comprising
Pirfenidone in a high concentration of more or less 25% by weight can be obtained by dissolving the active ingredient in a diethylene glycol monoethyl ether that is a medical solvent called Transcutol-P and described and its safety confirmed in the European and US pharmacopeias. It has also been found that the so obtained composition does not recrystallize if stored for a long period of time, able to be administered either orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip and certain to make a pharmaceutical composition excellent in every point. The present invention has been brought to completion on the basis of these findings .
The present invention provides a pharmaceutical liquid composition comprising as an active ingredient a pyridone derivative represented by the following formula (I) :
wherein R1 is an alkyl group optionally having a substituent and R2 is a phenyl group optionally having a substituent or a pharmaceutically acceptable salt thereof, and a . solvent .capable of dissolving said active ingredient in a high concentration. BEST MODE FOR CARRYING OUT THE INVENTION
The pharmaceutical liquid composition of the present invention comprises as the active ingredient a pyridone derivative represented by the above-mentioned formula (I) or a pharmaceutically acceptable salt thereof. In the above-mentioned formula (I) , R1 is an alkyl group optionally having a substituent and R2 is a phenyl group optionally having a substituent. The examples of the alkyl group optionally having a substituent as R1 include a C1-6 lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl and an alkyl group having a substituent in which said lower alkyl group is substituted with a halogen atom such as fluorine or chlorine; a carboxyl group; an alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl; or a substituent such as amino group. The alkyl group optionally having a substituent as R1 may be substituted at any of the 3-position, 4-position or 5-position. The examples of the phenyl group optionally having a substituent as R2 include a phenyl group and a phenyl group having a substituent in which the phenyl group is substituted with a Cx_6 lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl; a halogen atom such as fluorine or chlorine; a carboxyl group; an alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl; or a substituent such as amino group. For the pyridone derivative as the active ingredient, it is preferable to use the 5-methyl-l- phenyl-2- (IH) -pyridone (Pirfenidone) wherein R1 is a methyl group substituted at the 5-postion and R2 is a phenyl group. The pyridone derivative as the active ingredient may be a pharmaceutically acceptable salt thereof. The examples of the salt include an acid addition salt, a salt with alkali or the like. The example of the acid addition salt include an acid addition salt with an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, paratoluene sulfonic acid or methane sulfonic acid. The example of the salt with alkali includes a salt such as sodium salt or potassium salt. In the liquid composition of the present invention, it is preferable to use the diethylene glycol monoethyl ether (also known as ethoxy diglycol or diethylene glycol ethyl ether) as the solvent capable of dissolving the active ingredient in a high concentration. The diethylene glycol monoethyl ether is a compound represented by the following chemical formula:
C2H5-0-CH2-CH2-0-CH2-CH2-OH
According to the 3rd and 4th editions of European Pharmacopoeia, the compound occurs as colorless and transparent, well miscible with water, and has been marketed by the name of Transcutol P as a commonly used solvent. It has also been known that the compound can be used as an absorption promoter in medicine (Ritschel, W. et al . , Skin Pharmacol., (1191) 4, 235-245) . In the present invention, it is preferable to use the diethylene glycol monoethyl ether having a purity of 99% or higher, more preferably 99.7% or higher and most preferably 99.9% or higher.
The present invention has demonstrated that the Pirfenidone can be dissolved in a very high concentration' of more or less 25% by weight by selecting the diethylene glycol monoethyl ether among others as the solvent for Pirfenidone and thus that a liquid medicinal composition containing the Pirfenidone in a very high concentration can be obtained. This high concentration corresponds to the 300 mg dose of the drug in a solution of 2 ml, almost equivalent to the dosage of the same drug in common tablets presently used for oral administration. In addition to the pyridone derivative, for example, Pirfenidone as the active ingredient and the diethylene glycol monoethyl ether as the solvent, the liquid medicinal composition of the present invention can contain a concentrating agent, antioxidant, dispersant, viscosity adjusting agent, diluent, antimicrobial and the like that are commonly used in medicinal formulations, depending upon the method of administration, the route of administration, the specific type of formulation and the like. The examples of the concentrating agent include polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and the like. The examples of the antioxidant include sodium metabisulfite, α-tocopherol, sodium ascorbate and the like. The examples of the dispersant include polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose and the like. The examples of the viscosity adjusting agent include bentonite, calcium magnesium silicate and the like. The examples of the diluent include methanol, ethanol and the like. The examples of the antimicrobial include benzalkonium chloride, benzethonium chloride, methylparaben, ethylparaben and the like.
The liquid composition of the present invention has a broad spectrum of application in the administration via oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, injection or intravenous drip and the like. For example, the highly concentrated solution dissolving the pyridone derivative such as Pirfenidone in the solvent comprising diethylene glycol monoethyl ether is partially separated and the so separated liquid is diluted with water or fruit juice to make a pharmaceutical formulation for oral administration. The liquid composition of the present invention dissolves in a high concentration Pirfenidone which is slightly soluble in water by nature, accompanied by the hydration property permitting the composition to be diluted 4 to 5 times with water and make a pharmaceutical formulation for oral administration with ease. Furthermore, the liquid composition of the present invention is very low in viscosity and can be filled into a pump spray as a spray formulation' or into a roll-on container for use in oral, nasal or vaginal administration. Moreover, it also can be filled into, for example, a vaporizer such as nebulizer, to make a pharmaceutical formulation for vaporizing administration. Furthermore, an injection or intravenous drip can be prepared from the composition by adding isotonic physiological saline thereto. With respect to the liquid composition of the present invention, the preferred specific examples will be shown below:
Ingredients % by weight
Pirfenidone 1-25 Diethylene glycol monoethyl ether 70-80
Ethanol (95%) 0-10 Polyvinyl pyrrolidone or hydroxypropyl cellulose 0-3
Sodium metabisulfite 0.02-2
Methyl or propyl paraben 0-0.5
Purified water 0-25 Ingredients % by weight Pirfenidone 10-25 Diehtylene glycol monoethyl ether 75-80 Purified water 0-10
Ingredients % by weight Pirfenidone 10-25 Diethylene glycol monoethyl ether 75-80 α-Tocopherol 0.1-0.5 Hydroxypropyle cellulose 0-3 Purified water 0-10
The present invention will be explained in detail below, with reference to examples, but the present invention will not be limited by these examples in any way.
Examples 1 to 6:
The pharmaceutical liquid compositions were prepared from the formulations listed in Table 1.
That is, the diethylene glycol monoethyl ether was charged to a suitable container and warmed to 60 °C. The Pirfenidone was added while stirring and a yellowish solution was obtained by continuing the stirring until the mixture was transparent. All the remaining ingredients as listed in Table 1 were dissolved in water at 60 °C and this solution was poured into the above Pirfenidone solution and the stirring was continued . until mixed uniformly. The so obtained solution was protected from the light. The solutions of Examples 1 and 2 were found to have the viscosity similar to that of water. It was found that the solution of Example 5 had the slightly higher viscosity but was not in a state of gel and still pourable, while. the solutions of Examples 3 and 4 were found to have the viscosity similar to that of water.
Table 1
Figure imgf000012_0001
As shown in Table 1, the liquid compositions containing the Pirfenidone in the high concentrations could be obtained by dissolving the Pirfenidone in the diethylene glycol monoethyl ether.
Examples 7 to 11:
The liquid compositions were prepared, having the formulations listed in Table 2.
That is, the diethylene glycol monoethyl ether was charged to a suitable container and warmed to 60 °C, and the Pirfenidone was added while stirring and a yellowish solution was obtained by continuing the stirring until the whole became transparent.
Furthermore, the α-tocopherol was added and water was added while stirring until mixed uniformly. Then, the hydroxypropyl cellulose was added because of its necessity and stirred until a homogenous dispersion was formed. Furthermore, the dispersion was allowed to stand overnight until the particles of hydroxypropyl cellulose, the concentrating agent, were expanded, and finally the product was homogenized. The so obtained dispersion was allowed to stand overnight and a solution in the desired concentration was obtained.
The solution was homogenized again and protected from light. The solutions of Examples 7 and 8 were found to have the viscosity similar to that of water. Table 2
Figure imgf000014_0001
As shown in Table 2, the liquid compositions containing the Pirfenidone in the high concentrations could be obtained by dissolving the Pirfenidone in diethylene glycol monoethyl ether.
INDUSTRIAL APPLICABILITY
As described above, the Pirfenidone is dissolved in diethylene glycol monoethyl ether, with the result that the liquid medicinal compositions containing the Pirfenidone in very high concentrations of more or less 25% by weight are obtained. When these liquid compositions are stored at low temperatures for a long period of time, the Pirfenidone will not be recrystallized with a good chemical and physical stability. The liquid compositions have a broad spectrum of application in manufacturing the various different pharmaceutical formulations for use in administration via oral, percutaneous, nasal or vaginal routes or by means of spray, patch, inhalation, Injection or intravenous drip. The liquid compositions can undergo the sterilization in the manufacturing process for injections or intravenous drips and are well miscible when they are diluted in water and non- irritating when applied to the open wounds. Even if the liquid medicinal compositions are contained in non- aqueous pharmaceutical formulations, they will be very stable, having many different advantages.

Claims

CLAIMS 1. A pharmaceutical liquid composition comprising as an active ingredient a pyridone derivative represented by the following formula (I) :
Figure imgf000016_0001
wherein R1 is an alkyl group optionally having a substituent and R2 is a phenyl group optionally having a substituent or a pharmaceutically acceptable salt thereof, and a solvent capable of dissolving said active ingredient in a high concentration.
2. A pharmaceutical liquid composition according to Claim 1, comprising as the active ingredient a 5- methyl-l-phenyl-2- (IH) -pyridone (Pirfenidone) wherein R1 is a methyl group at the 5-position and R2 is a phenyl group in the formula (I) or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical liquid composition according to Claim 1 or 2, wherein the solvent is a diethylene glycol monoethyl ether.
4. A pharmaceutical liquid composition according to Claim 3, wherein the diethylene glycol monoethyl ether has a purity of 99% or higher.
5. A pharmaceutical liquid composition according to any one of Claims 1 to 4, further comprising a concentrating agent.
6. A pharmaceutical liquid composition according to any one of Claims 1 to 5, further containing an antioxidant.
7. A pharmaceutical liquid composition according to Claim 6, wherein the antioxidant is an α-tocopherol.
8. A pharmaceutical liquid composition according to any one of Claims 1 to 7, which is suitable to be administered orally, percutaneously, nasally or vaginally or as a spray, patch, inhalant, injection or intravenous drip.
9. A pharmaceutical liquid composition according to any one of Claims 1 to 8, having the following components :
Ingredients % by weight
Pirfenidone 1-25 Diethylene glycol ' monoethyl ether 70-80
Ethanol (95%) 0-10 Polyvinyl .pyrrolidone or hydroxypropyl cellulose 0-3
Sodium metabisulfite 0.02-2 Methyl or propyl paraben 0-0.5 Purified water 0-25
10. A pharmaceutical liquid composition according to any one of Claims 1 to 8, having the following components :
Ingredients % by weight
Pirfenidone 10-25
Diethylene glycol monoethyl ether 75-80 Purified water 0-10
11. A pharmaceutical liquid composition according to any one of Claims 1 to 8, having the following components :
Ingredients % by weight
Pirfenidone 10-25 Diethylene glycol monoethyl ether 75-80 α-Tocopherol 0.1-0.5 Hydroxypropyl cellulose 0-3 Purified water 0-10
PCT/JP2003/016599 2002-12-26 2003-12-24 Pharmaceutical liquid composition containing pyridone derivative WO2004058256A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003292551A AU2003292551A1 (en) 2002-12-26 2003-12-24 Pharmaceutical liquid composition containing pyridone derivative
US10/540,422 US7605173B2 (en) 2002-12-26 2003-12-24 Pharmaceutical liquid composition containing pyridone derivative
DE60332393T DE60332393D1 (en) 2002-12-26 2003-12-24 LIQUID PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
EP03768187A EP1575585B1 (en) 2002-12-26 2003-12-24 Pharmaceutical liquid composition containing pyridone derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002375834A JP4542743B2 (en) 2002-12-26 2002-12-26 Solution pharmaceutical composition of pyridone derivatives
JP2002-375834 2002-12-26

Publications (1)

Publication Number Publication Date
WO2004058256A1 true WO2004058256A1 (en) 2004-07-15

Family

ID=32677349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/016599 WO2004058256A1 (en) 2002-12-26 2003-12-24 Pharmaceutical liquid composition containing pyridone derivative

Country Status (6)

Country Link
US (1) US7605173B2 (en)
EP (1) EP1575585B1 (en)
JP (1) JP4542743B2 (en)
AU (1) AU2003292551A1 (en)
DE (1) DE60332393D1 (en)
WO (1) WO2004058256A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147169A2 (en) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemulsion containing pirfenidone
EP2177220A1 (en) * 2007-08-14 2010-04-21 Cell Therapy Technology, S.A. DE C.V. Gel containing pirfenidone
EP2359827A1 (en) * 2008-11-21 2011-08-24 Lead Chemical Co. Ltd. Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone
EP2670242A1 (en) * 2011-01-31 2013-12-11 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2014018668A2 (en) 2012-07-24 2014-01-30 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2014178065A1 (en) * 2013-04-02 2014-11-06 Themis Medicare Limited Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2022130410A1 (en) * 2020-12-16 2022-06-23 Cipla Limited Topical composition of pirfenidone
WO2024051687A1 (en) * 2022-09-06 2024-03-14 南京迈诺威医药科技有限公司 Topical formulation containing pirfenidone and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545813C (en) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
US7449441B2 (en) * 2005-05-18 2008-11-11 Toilex, Llc Liquid composition for reducing toilet odor
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
ES2611995T3 (en) * 2007-01-19 2017-05-11 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
JP5248040B2 (en) * 2007-05-25 2013-07-31 リードケミカル株式会社 Patch containing 5-methyl-1-phenyl-2- (1H) -pyridone
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
US20140187635A1 (en) * 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
JP6174374B2 (en) * 2013-05-22 2017-08-02 塩野義製薬株式会社 Pharmaceutical composition for inhalation
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN109758436A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation pirfenidone freeze-dried lipidosome preparation and preparation method thereof
US20230190681A1 (en) * 2021-12-16 2023-06-22 Hector Gonzales Topical Ointment Composition, Methods Of Use, And Methods Of Preparation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
GB1529960A (en) * 1974-12-09 1978-10-25 Affiliated Med Res Treating mammals with 5-methyl-1-phenyl-2-(1h)pyridone
EP0383591A2 (en) 1989-02-15 1990-08-22 Yamauchi, Shitotomo Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
WO2000041692A2 (en) * 1999-01-11 2000-07-20 The Procter & Gamble Company Compositions having improved stability
WO2001047495A1 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
WO2001058448A1 (en) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Apoptosis inhibitor
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2366349C2 (en) * 1972-12-18 1986-03-27 Affiliated Medical Research Inc., Princeton, N.J. Process for the preparation of 5-methyl-1-phenyl-2- (1H) -pyridone
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
DE69431433T2 (en) * 1993-05-07 2003-12-04 Solomon B Margolin COMPOSITIONS AND METHODS FOR REPAIRING AND PREVENTING FIBROTIC INJURIES
DE69810518D1 (en) * 1998-09-18 2003-02-06 Mepha Ag Aesch TOPICALLY ADMINISTRABLE ALKYL, PHENYL PYRIDONE MEDICINAL PRODUCTS
US6087393A (en) * 1999-06-10 2000-07-11 Igen, Inc. Stabilized vitamin C formulations
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
CH696420A5 (en) * 2002-09-13 2007-06-15 Mepha Ag New stable formulations of alkyl, phenyl-pyridones for topical use.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
GB1529960A (en) * 1974-12-09 1978-10-25 Affiliated Med Res Treating mammals with 5-methyl-1-phenyl-2-(1h)pyridone
EP0383591A2 (en) 1989-02-15 1990-08-22 Yamauchi, Shitotomo Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
WO2000041692A2 (en) * 1999-01-11 2000-07-20 The Procter & Gamble Company Compositions having improved stability
WO2001047495A1 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
WO2001058448A1 (en) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Apoptosis inhibitor
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1575585A4

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
WO2008147169A3 (en) * 2007-05-29 2009-01-22 Magana Castro Jose Agustin Rog Microemulsion containing pirfenidone
WO2008147169A2 (en) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemulsion containing pirfenidone
EP2177220A1 (en) * 2007-08-14 2010-04-21 Cell Therapy Technology, S.A. DE C.V. Gel containing pirfenidone
EP2177220A4 (en) * 2007-08-14 2013-09-11 Cell Therapy And Technology S A De C V Gel containing pirfenidone
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2359827A1 (en) * 2008-11-21 2011-08-24 Lead Chemical Co. Ltd. Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone
EP2359827A4 (en) * 2008-11-21 2013-01-02 Lead Chem Co Ltd Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012212269B2 (en) * 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2670242A4 (en) * 2011-01-31 2015-02-25 Genoa Pharmaceuticals Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4059499A1 (en) * 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2016213708B2 (en) * 2011-01-31 2018-05-10 Avalyn Pharma Inc. Aerosol pirfenidone and pyridine analog compounds and uses thereof
EP2670242A1 (en) * 2011-01-31 2013-12-11 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2014018668A2 (en) 2012-07-24 2014-01-30 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2877164A4 (en) * 2012-07-24 2016-01-13 Genoa Pharmaceuticals Inc Aerosol pirfenidone and pyridone analog compounds
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
KR101875263B1 (en) * 2013-04-02 2018-07-05 테미스 메디케어 리미티드 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
CN105392469A (en) * 2013-04-02 2016-03-09 西弥斯医疗有限公司 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
WO2014178065A1 (en) * 2013-04-02 2014-11-06 Themis Medicare Limited Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
AU2014261009B2 (en) * 2013-04-02 2017-05-04 Themis Medicare Limited Compositions of pharmaceutical actives containing Diethylene glycol monoethyl ether or other alkyl derivatives
US10028966B2 (en) 2014-01-10 2018-07-24 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
WO2022130410A1 (en) * 2020-12-16 2022-06-23 Cipla Limited Topical composition of pirfenidone
WO2024051687A1 (en) * 2022-09-06 2024-03-14 南京迈诺威医药科技有限公司 Topical formulation containing pirfenidone and use thereof

Also Published As

Publication number Publication date
DE60332393D1 (en) 2010-06-10
US7605173B2 (en) 2009-10-20
JP2004203795A (en) 2004-07-22
EP1575585B1 (en) 2010-04-28
AU2003292551A1 (en) 2004-07-22
EP1575585A1 (en) 2005-09-21
EP1575585A4 (en) 2008-04-02
JP4542743B2 (en) 2010-09-15
US20060167064A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
US7605173B2 (en) Pharmaceutical liquid composition containing pyridone derivative
ES2369089T3 (en) WATERY OPTICAL DROPS WITH ACCELERATED INTRAOCULAR MIGRATION.
JPS62155216A (en) Dihydropyridine spray
IL100330A (en) 3-[2(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulphonamide sulphate salt (2:1) process for its preparation and pharmaceutical composition containing it
HU195918B (en) Process for producing pharmaceutical compositions containing non-steroide antiflogistic active components
EP1895983A2 (en) Injectable compositions and process for preparation of such compositions
CN1993115B (en) Compound formulations of 2-amino-1, 3-propanediol compounds
JPH1160505A (en) Antiseptic composition
EP0604570B1 (en) Compositions containing quinolone antibiotics and sulfonate of polystyrol
KR20070059154A (en) Nonaqueous liquid parenteral aceclofenac formulation
TW202114661A (en) Pharmaceutical composition containing antifungal agent as active ingredient
WO1993003723A1 (en) Leukotriene receptor antagonist-antihistamine complex
WO2021124044A1 (en) Pharmaceutical composition of cyclooxygenase – 2 inhibitors
EP0055593B1 (en) Compositions comprising e-prostaglandins
JP2005247799A (en) Eye drop
JP2005247795A (en) Stable eye drops
JP2005247798A (en) Eye drop
JP2002037735A (en) Method for stabilizing caffeines and composition to be applied to mucous membrane
KR100599334B1 (en) Injectible Composition Comprising Flofenicol
CN102202651A (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
US7645765B2 (en) Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
HU211580A9 (en) Piroxicam solutions of increased stability without tissue-damaging effect
JP2000247883A (en) Liquid agent for internal use containing dihydropyridine- based compound
WO2003035063A1 (en) Novel preparation of selective cyclooxygenase ii inhibitors
JP2005247797A (en) Eye drop

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003768187

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003768187

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006167064

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10540422

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10540422

Country of ref document: US